The first Seagen trade was made in Q3 2015. Since then Paul Tudor Jones II bought shares fourteen more times and sold shares on eighteen occasions. The investor completely sold their stake between Q4 2023 and Q4 2023.
GSK plc (LON/NYSE: GSK) has announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluat...
Seagen Inc. (NASDAQ: SGEN) today announced an update to the U.S. Prescribing Information (PI) for ADCETRIS (brentuximab vedotin) to include six-year overall ...
Merck will pay US$200 per share for the California-based biotechnology company that specialises in treatments for autoimmune diseases. That represents a 75% ...